Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.78 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.78 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | CASP6 | P55212 | 1/20 | 0.58 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.54 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.50 |
| ▸ | CDC42 | P60953 | 1/20 | 0.48 |
| ▸ | RB1 | P06400 | 5/20 | 0.46 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CDKN1A | P38936 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20537339 | 1.00 | CYP2D6 (0.78) | CYP2D6KCNH2GAACASP6PRMT5 | |
| SCHEMBL4194153 | 1.00 | CYP2D6 (0.78) | CYP2D6KCNH2GAACASP6PRMT5 | |
| SCHEMBL4199294 | 1.00 | CYP2D6 (0.78) | CYP2D6KCNH2GAACASP6PRMT5 | |
| SCHEMBL5461901 | 1.00 | CYP2D6 (0.78) | CYP2D6KCNH2GAACASP6PRMT5 | |
| SCHEMBL4195673 | 1.00 | CYP2D6 (0.78) | CYP2D6KCNH2GAACASP6PRMT5 | |
| SCHEMBL4194377 | 1.00 | CYP2D6 (0.78) | CYP2D6KCNH2GAACASP6PRMT5 | |
| SCHEMBL4172408 | 1.00 | CYP2D6 (0.78) | CYP2D6KCNH2GAACASP6PRMT5 | |
| SCHEMBL20537338 | 1.00 | CYP2D6 (0.78) | CYP2D6KCNH2GAACASP6PRMT5 | |
| Hydrochloric Acid SCHEMBL4152184 | 0.99 | CYP2D6 (0.77) | CYP2D6KCNH2GAACASP6PRMT5 | |
| Hydrochloric Acid SCHEMBL4165920 | 0.99 | CYP2D6 (0.77) | CYP2D6KCNH2GAACASP6PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110914270-B | Preparation method of pirlindole enantiomer and salt thereof | 社会医疗技术员技术股份公司 | 2022-05-03 | — | — | CN | claimed |
| EP-1658068-B1 | NOVEL CYCLOALKYL[B] CONDENSED INDOLES | SMITHKLINE BEECHAM CORP (US) | 2009-02-18 | — | — | EP | claimed |
| CN-110914270-B | Preparation method of pirlindole enantiomer and salt thereof | 社会医疗技术员技术股份公司 | 2022-05-03 | — | — | CN | disclosed |
| US-20150210717-A1 | SPECIFIC INHIBITORS OF PROTEIN P21 AS THERAPEUTIC AGENTS | LEIBNIZ-INSTITUT FÜR ALTERSFORSCHUNG (DE) | 2015-07-30 | — | — | US | disclosed |
| US-20150210717-A1 | SPECIFIC INHIBITORS OF PROTEIN P21 AS THERAPEUTIC AGENTS | LEIBNIZ-INSTITUT FÜR ALTERSFORSCHUNG (DE) | 2015-07-30 | — | — | US | disclosed |
| WO-2014041125-A1 | SPECIFIC INHIBITORS OF PROTEIN P21 AS THERAPEUTIC AGENTS | BADEN-WÜRTTEMBERG STIFTUNG GMBH (DE) | 2014-03-20 | — | — | WO | disclosed |
| US-7622494-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622494-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622494-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-24 | — | — | US | disclosed |
| US-20090170923-A1 | HCV INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-07-02 | — | — | US | disclosed |
| US-20090170923-A1 | HCV INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-07-02 | — | — | US | disclosed |
| US-20090170923-A1 | HCV INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-07-02 | — | — | US | disclosed |
| EP-1658068-B1 | NOVEL CYCLOALKYL[B] CONDENSED INDOLES | SMITHKLINE BEECHAM CORP (US) | 2009-02-18 | — | — | EP | disclosed |
| US-20060281804-A1 | Novel cycloalkyl'b! condensed indoles | SMITHKLINE BEECHAM CORPORATION | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170923-A1 | HCV INHIBITORS | HAVCR2, MAVS, EIF2AK2 | CYP2D6 994/4885KCNH2 4356/4885GAA 908/4885 |
| US-20150210717-A1 | SPECIFIC INHIBITORS OF PROTEIN P21 AS THERAPEUTIC AGENTS | CDKN1A, ING2, BCCIP | CYP2D6 4797/4885KCNH2 4759/4885GAA 3655/4885 |
| US-20060281804-A1 | Novel cycloalkyl'b! condensed indoles | BCCIP, TP53, TOP2B | CYP2D6 3945/4885KCNH2 3846/4885GAA 4529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.